Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 76-84

  Choi, Brian G ^a   Vilahur, Gemma ^a   Zafar, M Urooj ^a   Cardoso, Luis ^a   Yadegar, Daniel ^a   Ibanez, Borja ^a   Tunstead, James ^a   Viles Gonzalez, Juan F ^a   Schaffler, Mitchell B ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Inflammation; Osteoporosis; Selective estrogen receptor modulator (SERM); Vascular calcification

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; INFLAMMATION; LOW DRUG DOSE; MACROPHAGE; MENOPAUSE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RECEPTOR UPREGULATION; THROMBOCYTE AGGREGATION;

ANIMALS; ATHEROSCLEROSIS; CHEMOKINE CCL2; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE 1; MENOPAUSE; OSTEOPOROSIS; OVARIECTOMY; RABBITS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 53849129582     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.01.017     Document Type: Article

References (45)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation; 2006.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
3. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
5. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 (2002) 847-857
6. Mosca L., Barrett-Connor E., Wenger N.K., et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88 (2001) 392-395
7. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137
8. Bjarnason N.H., Haarbo J., Byrjalsen I., Kauffman R.F., and Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96 (1997) 1964-1969
9. Bjarnason N.H., Haarbo J., Byrjalsen I., et al. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol (Oxf) 52 (2000) 225-233
10. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 356 (2007) 2591-2602
11. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
12. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
13. Raggi P., Davidson M., Callister T.Q., et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 112 (2005) 563-571
14. Zhou S., Turgeman G., Harris S.E., et al. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol Endocrinol 17 (2003) 56-66
15. Garfinkel A., Tintut Y., Petrasek D., Bostrom K., and Demer L.L. Pattern formation by vascular mesenchymal cells. Proceedings of the national academy of sciences of the United States of America 101 (2004) 9247-9250
16. Emmanuele L., Ortmann J., Doerflinger T., Traupe T., and Barton M. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 302 (2003) 67-72
17. Abedin M., Tintut Y., and Demer L.L. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24 (2004) 1161-1170
18. Viles-Gonzalez J.F., Fuster V., Corti R., et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. Eur Heart J 26 (2005) 1557-1561
19. Corti R., Osende J.I., Fallon J.T., et al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 43 (2004) 464-473
20. Corti R., Osende J., Hutter R., et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. Atherosclerosis (2006)
21. Zhang Z., Machac J., Helft G., et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 6 (2006) 3
22. Helft G., Worthley S.G., Fuster V., et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation 105 (2002) 993-998
23. Helft G., Worthley S.G., Fuster V., et al. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. J Am Coll Cardiol 37 (2001) 1149-1154
24. Choi B.G., Vilahur G., Cardoso L., et al. Ovariectomy increases vascular calcification via the opg/rankl cytokine signaling pathway. Eur J Clin Invest 38 (2008) 211-217
25. Fritton J.C., Chinitz N., Berman D., et al. Atherogenic treatment impairs age-related cortical bone adaptation in female rabbits. J Orthop Res (2007). http://www.ors.org/web/Transactions/53/1396.PDF http://www.ors.org/web/Transactions/53/1396.PDF: Abstract
26. Choi B.G., Novoselsky C.A., Vilahur G., et al. Validation study of a semi-automated program for quantification of atherosclerotic burden. J Cardiovas Magn Reson 9 (2008) 615-620
27. Galvez A., Badimon L., Badimon J.J., and Fuster V. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost 56 (1986) 128-132
28. Toussaint J.F., Southern J.F., Fuster V., and Kantor H.L. T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler Thromb Vasc Biol 15 (1995) 1533-1542
29. Pearlman J.D., Zajicek J., Merickel M.B., et al. High-resolution 1H NMR spectral signature from human atheroma. Magn Reson Med 7 (1988) 262-279
30. Wolf R.L., Wehrli S.L., Popescu A.M., et al. Mineral volume and morphology in carotid plaque specimens using high-resolution MRI and CT. Arterioscler Thromb Vasc Biol 25 (2005) 1729-1735
31. Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst, Man Cybern 9 (1979) 62-66
32. Fujii K., Carlier S.G., Mintz G.S., et al. Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques. Am J Cardiol 96 (2005) 352-357
33. Barkhem T., Carlsson B., Nilsson Y., et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54 (1998) 105-112
34. Seli E., Pehlivan T., Selam B., Garcia-Velasco J.A., and Arici A. Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertil Steril 77 (2002) 542-547
35. Belton O., and Fitzgerald D.J. Cyclooxygenase isoforms and atherosclerosis. Expert Rev Mol Med 5 (2003) 1-18
36. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
37. Jayachandran M., Mukherjee R., Steinkamp T., et al. Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am J Physiol Heart Circ Physiol 288 (2005) H2355-H2362
38. Polini N., Rauschemberger M.B., Mendiberri J., Selles J., and Massheimer V. Effect of genistein and raloxifene on vascular dependent platelet aggregation. Mol Cell Endocrinol 267 (2007) 55-62
39. Blumenthal R.S., Baranowski B., and Dowsett S.A. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 147 (2004) 783-789
40. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348 (2003) 618-629
41. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 (2002) 2884-2887
42. Hodgin J.B., Krege J.H., Reddick R.L., et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 107 (2001) 333-340
43. Mayer L.P., Devine P.J., Dyer C.A., and Hoyer P.B. The follicle-deplete mouse ovary produces androgen. Biol Reprod 71 (2004) 130-138
44. Bellino FL. Nonprimate animal models of menopause: workshop report. Menopause (New York, N.Y) 2000;7:14-24.
45. Mayer L.P., Dyer C.A., Eastgard R.L., Hoyer P.B., and Banka C.L. Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. Arterioscler, Thromb Vasc Biol 25 (2005) 1910-1916